

# **From courses to careers: A Pharmaceutical perspective**

**Brad Evans, Ph.D.**

**Pfizer Global Research and Development**

# Specific Opportunities

- **Preclinical – Discovery**
- **PDM**
- **Toxicology**
- **Pharmaceutical Sciences**
- **Drug manufacturing**
  - A series of funnels or filters**
- **Apply Statistical methods to help drive decisions**

# Early Discovery

- Find something that does something..
- Target: scientific literature, market research
- High Throughput Screening / Discovery Biology
  - DOE for Assay Design
  - Control Charting
  - Exploratory Data Analysis
  - Non-linear Dose Response Models
  - Multiple Comparisons
  - Structure Activity Relationship (PLS, SVM, etc)
- How do we modify a molecule that is “close”?
- How do we select which compounds will continue?

# Early Discovery

- Dose Response / Non Linear Model
  - Variance – constant, proportional?
  - Transform:  $x?$ ,  $y?$  both?
- Data fitting or coefficients with intrinsic meaning?
  - Rate of binding
  - Coefficients may tell the scientists what mechanism(s) are at work
- 2x2 table but 99%+ in one cell?

# PDM (Pharmacokinetics, Dynamics and Metabolism)

- ▣ What the drug does to the body
- ▣ What the body does to the drug
- ▣ More in-depth information on fewer compounds..
- ▣ Dose response:
  - ▣  $T_{max}$ ,  $C_{max}$ , AUC, half-life
  - ▣ Non-linear modeling
- ▣ Battery of safety assays
- ▣ How do we “build” and assess the assays?
- ▣ How do we select which compounds continue?
- ▣ Is the “best” good enough?
- ▣ Do in-vitro (lab) and in-vivo (animal) data:
  - ▣ Correlate?
  - ▣ Substitute?

# Safety / Toxicology

- How does the drug perform in animal studies?
  - Is there a dose response?
  - Is there a safety window?
  - Are any systems negatively impacted?
    - Kidney, liver, brain, body weight, heart function?
  - Are the offspring impacted? (Thalidomide)
  - Limited “n” (want to “prove” no Adverse Events)
- One study may “kill” a compound
- ANOVA, Dose trending, multiple comparisons
- Reporting, validation and documentation much more stringent compared to early discovery

# Pharmaceutical Development

- If a compound works, how can we make it?
  - Chemical synthesis (DOE, EDA)
  - Biological process – grow cells, clean cells (DOE)
- How can we test it? (Analytical methods)
  - Method development
  - Method precision, linearity, bias, robustness
  - Do we have uniformity in our tablets and capsules?
  - Does our delayed release formulation work as intended?
- How can we preserve its functionality over time?
  - Formulation (DOE, Mixture Experiments)
  - Stability Testing (Regression, ANCOVA)
- Overall, do all three pieces above have a robust, controlled process? (Quality by Design)
  - Lab → Pilot → Commercial scale (DOE, modeling)
  - Testing to support label claims, product performance over time

# Global Supply (Manufacturing)

- Process Control, process capability
- Investigational work , annual reviews
- What process variables are contributing to process variation?
- Changes: facility, supplier, method, reagent
- Can we improve our process: time, \$\$, greener?
  - DOE
  - Total Quality Management / Six Sigma